<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00931476</url>
  </required_header>
  <id_info>
    <org_study_id>GHKIN-1253</org_study_id>
    <nct_id>NCT00931476</nct_id>
  </id_info>
  <brief_title>A Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Somatropin</brief_title>
  <official_title>A Single-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group, Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Norditropin® (Norditropin® PenSet® 24)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial was conducted in the United States of America (USA). The aim of this clinical
      trial was to investigate the pharmacokinetics of somatropin in healthy Japanese and Caucasian
      subjects, and to identify somatostatin-related adverse events.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 6, 2000</start_date>
  <completion_date type="Actual">June 8, 2000</completion_date>
  <primary_completion_date type="Actual">June 8, 2000</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the hGH concentration-time curve (GH AUC0-24h)</measure>
    <time_frame>from 0 to 24 hours following injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum hGH concentration (GH Cmax)</measure>
    <time_frame>from 0 to 24 hours following injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment Emergent Adverse Events</measure>
    <time_frame>from 0 to 24 hours following injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to maximum hGH concentration (GH tmax)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the hGH concentration-time curve GH AUC0-∞)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life (GH t½)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth Factors (IGF-I and IGFBP-3)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-treatment Emergent Adverse Events</measure>
  </secondary_outcome>
  <enrollment type="Actual">86</enrollment>
  <condition>Growth Hormone Disorder</condition>
  <condition>Adult Growth Hormone Deficiency</condition>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>somatropin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent before any trial related activities

          -  Japanese and Caucasian males respectively

          -  Healthy subjects based upon medical history, physical examination, vital signs, ECG,
             serum biochemistry and haematology and urinalysis

          -  Body Mass Index (BMI) between 17 and 30 m2/kg, inclusive
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814-4224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2009</study_first_submitted>
  <study_first_submitted_qc>June 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2009</study_first_posted>
  <last_update_submitted>February 23, 2017</last_update_submitted>
  <last_update_submitted_qc>February 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dwarfism, Pituitary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

